Schacht, Joseph P. http://orcid.org/0000-0003-4250-0495
Yeongbin Im,
Hoffman, Michaela
Voronin, Konstantin E.
Book, Sarah W.
Anton, Raymond F. http://orcid.org/0000-0003-3417-6576
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (P50 AA010761, R01 AA026859, R00 AA021419)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism
Article History
Received: 7 March 2022
Revised: 8 April 2022
Accepted: 25 April 2022
First Online: 6 May 2022
Competing interests
: In the past 3 years, Dr Anton has been a consultant for Alkermes, Denovo, Dicerna, Foxo Bioscience, Imbrium, Otsuka, and Sophrosyne Pharma, and has received grant funding from Laboratorio Farmaceutico C.T. He is chair of and a participant in the Alcohol Clinical Trials Initiative (ACTIVE), which is sponsored by the American Society of Clinical Psychopharmacology and has been supported (in the past or currently) by Abbvie, Alkermes, Amygdala, Arbor, Dicerna, Ethypharm, Glaxo Smith Kline, Indivior, Janssen, Eli Lilly, Lundbeck, Mitsubishi, Otsuka, Pfizer, and Schering. In the past 3 years, Dr Schacht has received grant funding from Laboratorio Farmaceutico C.T. Drs Hoffman, Voronin, and Book and Ms Im report no biomedical competing interests.
Free to read: This content has been made available to all.